Healthcare Value Capital Has Lifted Depomed (Put) (DEPO) Position by $1.60 Million; Patten & Patten Upped Its Position in Edwards Lifesciences Corp. (EW) by $748,830

January 14, 2018 - By Vivian Currie

Healthcare Value Capital Llc increased its stake in Depomed Inc (Put) (DEPO) by 320% based on its latest 2017Q3 regulatory filing with the SEC. Healthcare Value Capital Llc bought 320,000 shares as the company’s stock declined 38.37% while stock markets rallied. The hedge fund held 420,000 shares of the health care company at the end of 2017Q3, valued at $2.43M, up from 100,000 at the end of the previous reported quarter. Healthcare Value Capital Llc who had been investing in Depomed Inc (Put) for a number of months, seems to be bullish on the $524.90 million market cap company. The stock decreased 1.65% or $0.14 during the last trading session, reaching $8.33. About 488,076 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 46.86% since January 14, 2017 and is downtrending. It has underperformed by 63.56% the S&P500.

Patten & Patten Inc increased its stake in Edwards Lifesciences Corp. (EW) by 12.45% based on its latest 2017Q3 regulatory filing with the SEC. Patten & Patten Inc bought 6,870 shares as the company’s stock rose 25.80% with the market. The institutional investor held 62,050 shares of the industrial specialties company at the end of 2017Q3, valued at $6.78M, up from 55,180 at the end of the previous reported quarter. Patten & Patten Inc who had been investing in Edwards Lifesciences Corp. for a number of months, seems to be bullish on the $25.57 billion market cap company. The stock increased 0.70% or $0.84 during the last trading session, reaching $120.83. About 1.03 million shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since January 14, 2017 and is uptrending. It has underperformed by 1.29% the S&P500.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 21 have Buy rating, 1 Sell and 6 Hold. Therefore 75% are positive. Edwards Lifesciences Corp had 93 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Friday, December 8 by Canaccord Genuity. The stock has “Mkt Perform” rating by JMP Securities on Wednesday, January 6. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Overweight” rating given on Monday, April 11 by JP Morgan. The rating was upgraded by Bank of America on Thursday, July 27 to “Buy”. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Buy” rating given on Tuesday, September 5 by Jefferies. Canaccord Genuity maintained Edwards Lifesciences Corporation (NYSE:EW) on Sunday, October 8 with “Buy” rating. BTIG Research downgraded the stock to “Neutral” rating in Thursday, February 2 report. The stock has “Buy” rating by Jefferies on Friday, May 26. The firm has “Equalweight” rating by Barclays Capital given on Wednesday, July 27. Cowen & Co maintained the shares of EW in report on Wednesday, April 27 with “Outperform” rating.

Patten & Patten Inc, which manages about $1.33 billion and $949.05M US Long portfolio, decreased its stake in Canadian National Railway Co. (NYSE:CNI) by 5,444 shares to 133,353 shares, valued at $11.06 million in 2017Q3, according to the filing. It also reduced its holding in American International Group I (NYSE:AIG) by 42,580 shares in the quarter, leaving it with 100,044 shares, and cut its stake in Apple Inc Com (NASDAQ:AAPL).

Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc had 50 analyst reports since July 30, 2015 according to SRatingsIntel. WallachBeth Capital maintained the stock with “Buy” rating in Wednesday, February 24 report. RBC Capital Markets maintained the shares of DEPO in report on Thursday, September 14 with “Hold” rating. UBS maintained Depomed, Inc. (NASDAQ:DEPO) rating on Monday, October 3. UBS has “Neutral” rating and $26 target. On Monday, December 12 the stock rating was downgraded by PiperJaffray to “Underweight”. On Tuesday, August 8 the stock rating was maintained by RBC Capital Markets with “Hold”. The stock of Depomed, Inc. (NASDAQ:DEPO) earned “Buy” rating by UBS on Tuesday, February 9. As per Wednesday, November 4, the company rating was initiated by Cantor Fitzgerald. The firm earned “Neutral” rating on Thursday, January 7 by Mizuho. The company was downgraded on Tuesday, February 14 by Mizuho. The company was downgraded on Monday, December 12 by Piper Jaffray.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.34, from 0.87 in 2017Q2. It increased, as 23 investors sold DEPO shares while 40 reduced holdings. 24 funds opened positions while 52 raised stakes. 56.42 million shares or 3.13% more from 54.71 million shares in 2017Q2 were reported. Deutsche Bancorp Ag reported 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). Hussman Strategic Inc reported 0.07% in Depomed, Inc. (NASDAQ:DEPO). Globeflex Capital LP holds 0.07% in Depomed, Inc. (NASDAQ:DEPO) or 41,631 shares. The Colorado-based Alps Advisors has invested 0% in Depomed, Inc. (NASDAQ:DEPO). 71,446 were reported by Alliancebernstein Limited Partnership. Barclays Public Limited reported 5,400 shares or 0% of all its holdings. Wisconsin-based 1492 Capital Limited has invested 0.07% in Depomed, Inc. (NASDAQ:DEPO). Bogle Management Lp De owns 955,191 shares for 0.38% of their portfolio. Franklin Res Inc holds 12,899 shares or 0% of its portfolio. Ahl Prns Llp reported 0% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). The Minnesota-based Thrivent Fincl For Lutherans has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Hartford Invest accumulated 13,700 shares or 0% of the stock. Hutchin Hill Capital Ltd Partnership invested in 164,600 shares. Nordea Invest Management Ab owns 0% invested in Depomed, Inc. (NASDAQ:DEPO) for 356,681 shares. Us Commercial Bank De accumulated 5,562 shares.

Since December 14, 2017, it had 1 buying transaction, and 0 sales for $612,000 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts